# Extension Study in a Cohort of Adult Patients With COVID-19 Infection

> **NCT05121740** · PHASE1,PHASE2 · COMPLETED · sponsor: **PharmaMar** · enrollment: 34 (actual)

## Conditions studied

- COVID-19 Infection

## Interventions

- **DRUG:** Plitidepsin 1.5 mg / day
- **DRUG:** Plitidepsin 2.0 mg / day
- **DRUG:** Plitidepsin 2.5 mg / day

## Key facts

- **NCT ID:** NCT05121740
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-25
- **Primary completion:** 2022-03-16
- **Final completion:** 2022-03-16
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05121740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05121740, "Extension Study in a Cohort of Adult Patients With COVID-19 Infection". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05121740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*